iRhythm Technologies, Inc.

DB:I25 Stock Report

Market Cap: €2.4b

iRhythm Technologies Valuation

Is I25 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of I25 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: I25 (€76.5) is trading above our estimate of fair value (€10.21)

Significantly Below Fair Value: I25 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for I25?

Key metric: As I25 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for I25. This is calculated by dividing I25's market cap by their current revenue.
What is I25's PS Ratio?
PS Ratio4.5x
SalesUS$560.03m
Market CapUS$2.52b

Price to Sales Ratio vs Peers

How does I25's PS Ratio compare to its peers?

The above table shows the PS ratio for I25 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.8x
AFX Carl Zeiss Meditec
2.5x7.9%€5.2b
EUZ Eckert & Ziegler
2.9x6.0%€802.1m
DRW3 Drägerwerk KGaA
0.2x4.2%€792.8m
SBS Stratec
1.4x7.7%€353.7m
I25 iRhythm Technologies
4.5x15.0%€2.5b

Price-To-Sales vs Peers: I25 is expensive based on its Price-To-Sales Ratio (4.5x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does I25's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$834.66m
PHH2 Paul Hartmann
0.3xn/aUS$751.55m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
I25 4.5xIndustry Avg. 3.4xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: I25 is expensive based on its Price-To-Sales Ratio (4.5x) compared to the European Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is I25's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

I25 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.5x
Fair PS Ratio4.1x

Price-To-Sales vs Fair Ratio: I25 is expensive based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (4.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst I25 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€76.50
€90.69
+18.5%
14.4%€115.35€72.90n/a11
Nov ’25€67.50
€90.69
+34.3%
14.4%€115.35€72.90n/a11
Oct ’25€64.00
€107.29
+67.6%
10.5%€129.86€89.56n/a10
Sep ’25€65.50
€105.84
+61.6%
9.3%€130.56€90.04n/a11
Aug ’25€80.00
€121.67
+52.1%
9.3%€151.35€105.49n/a11
Jul ’25€99.50
€126.51
+27.2%
8.9%€154.11€107.41n/a11
Jun ’25€82.00
€127.72
+55.8%
7.7%€153.27€113.33n/a10
May ’25€100.00
€130.34
+30.3%
6.8%€155.28€124.23n/a10
Apr ’25€106.00
€127.57
+20.4%
6.8%€151.98€121.59n/a10
Mar ’25€106.00
€127.70
+20.5%
6.8%€152.13€121.70n/a10
Feb ’25€111.00
€120.40
+8.5%
11.1%€152.00€101.33n/a10
Jan ’25€97.50
€115.16
+18.1%
11.8%€149.97€98.16n/a10
Dec ’24€77.50
€105.66
+36.3%
20.4%€153.88€79.27n/a10
Nov ’24€73.50
€122.25
+66.3%
17.4%€156.01€94.55€67.5010
Oct ’24€90.50
€128.30
+41.8%
11.1%€152.74€106.46€64.0010
Sep ’24€94.50
€128.30
+35.8%
11.1%€152.74€106.46€65.5010
Aug ’24€94.50
€126.29
+33.6%
9.2%€138.04€102.42€80.0010
Jul ’24€95.00
€132.76
+39.8%
9.2%€143.79€106.69€99.509
Jun ’24€104.00
€138.51
+33.2%
5.7%€150.61€122.49€82.009
May ’24€122.00
€133.70
+9.6%
9.5%€154.28€117.98€100.009
Apr ’24€112.00
€134.92
+20.5%
11.9%€159.25€104.27€106.009
Mar ’24€110.00
€134.92
+22.7%
11.9%€159.25€104.27€106.009
Feb ’24€89.00
€136.34
+53.2%
13.2%€157.84€103.35€111.008
Jan ’24€87.00
€141.03
+62.1%
12.6%€158.22€103.60€97.508
Dec ’23€104.00
€153.84
+47.9%
9.1%€178.52€134.37€77.507
Nov ’23€131.00
€172.40
+31.6%
15.5%€201.19€108.72€73.509

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$50.67

7D

-4.0%

1Y

-19.2%

Fagron

€1.4b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

4A5

€18.54

7D

-1.2%

1Y

9.3%

Shandong Weigao Group Medical Polymer

HK$20.4b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-9.5%

1Y

-41.3%